Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$17.06

-1.48 (-7.98%)

, JNJ

Johnson & Johnson

$137.94

-1.16 (-0.83%)

10:30
10/04/18
10/04
10:30
10/04/18
10:30

Arrowhead price target raised to $24 from $18 at Cantor Fitzgerald

Cantor Fitzgerald analyst Justin Kim raised his price target for Arrowhead (ARWR) to $24 from $18 following a newly announced collaboration and license agreement with Johnson & Johnson's (JNJ) subsidiary Janssen. Overall, the analyst feels the agreement is positive for the company as the support of a large partner could speed up the development timelines, increase market penetration with expertise, and validates the TRiM platform that Arrowhead uses. The additional cash will support Arrowhead's internal clinical development, he adds. Kim reiterates an Overweight rating on Arrowhead's shares.

ARWR

Arrowhead

$17.06

-1.48 (-7.98%)

JNJ

Johnson & Johnson

$137.94

-1.16 (-0.83%)

  • 16

    Oct

  • 28

    Oct

  • 09

    Nov

ARWR Arrowhead
$17.06

-1.48 (-7.98%)

10/04/18
PIPR
10/04/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead price target raised to $25 from $17 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead (ARWR) to $25 from $17 after the company signed a license and collaboration agreement with Johnson & Johnson's (JNJ) Janssen Pharmaceuticals to develop and commercialize ARO-HBV and up to 3 new TRiM candidates. The analyst notes that Arrowhead will receive $175M cash up front, a $75M equity investment, up to $3.5B in milestones plus up to mid-teens royalties on ARO-HBV. Tenthoff views this deal as transformative for Arrowhead, dramatically strengthening the balance sheet and finding a strong partner for ARO-HBV, while retaining the rest of TRiM pipeline. He reiterates an Overweight rating on Arrowhead's shares.
09/14/18
JEFF
09/14/18
NO CHANGE
Target $24
JEFF
Buy
Arrowhead price target raised to $24 from $20 at Jefferies
Jefferies analyst Maury Raycroft raised his price target for Arrowhead Pharmaceuticals to $24 after the company last week reported initial ARO-HBV data at the World Gastroenterologists Summit. The update was unexpected and an early glimpse into what should be a more mature, robust dataset at the American Association for the Study of Liver Diseases meeting, Raycroft tells investors in a research note. He sees the de-risking as a positive and keeps a Buy rating on Arrowhead.
09/06/18
CHDN
09/06/18
NO CHANGE
Target $24.5
CHDN
Buy
Arrowhead price target raised to $24.50 from $17.50 at Chardan
Chardan analyst Keay Nake raised Buy rated Arrowhead's price target to $24.50 from $17.50 to reflect increased confidence in the probability of success for the hepatitis B virus franchise.
09/06/18
PIPR
09/06/18
NO CHANGE
Target $17
PIPR
Overweight
Piper impressed by Arrowhead data, reiterates Overweight rating
Arrowhead Pharmaceuticals presented positive initial safely and efficacy data on ARO-HBV from the lowest two dose cohorts, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. All eight hepatitis B virus patients responded with a mean 2.0log HBsAg reduction to day 84 and 1.4log reduction to day 71 for the 100mg and 200mg cohorts, respectively, Tenthoff points out. The analyst finds the magnitude of HBsAg reduction with infrequent monthly dosing impressive and reiterates an Overweight rating on Arrowhead with a $17 price target.
JNJ Johnson & Johnson
$137.94

-1.16 (-0.83%)

10/03/18
WBLR
10/03/18
NO CHANGE
WBLR
Outperform
Janssen termination inconsequential for Aduro Biotech, says William Blair
William Blair analyst Matt Phipps attributes the 13% pullback yesterday in shares of Aduro Biotech (ADRO) to the termination of the company's collaboration with Johnson & Johnson's (JNJ) Janssen Biotech. Janssen officially ended a license agreement for two strains of Aduro's engineered Listeria therapy for lung and prostate cancers. Based on prior data with the Listeria strains and Aduro's decision to discontinue internal development of this platform at the end of 2017, Janssen's decision is not surprising, Phipps tells investors in a research note. The analyst views the news as inconsequential for Aduro and notes he did not consider the program a driver of Aduro valuation. The analyst did not include any aspect of the program in his estimates for Aduro and keeps an Outperform rating on the shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
09/14/18
WELS
09/14/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $150 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Johnson & Johnson to $160 after the company hosted an investor call to provide an update on its Pharmaceuticals business. The analyst heard no strategic change to the business saying J&J maintains focus on its six key therapeutic areas and remains agnostic to the source of innovation. While the company did not provide 2019 guidance, management's tone came across as confident in the business outlook, Biegelsen tells investors in a research note. He keeps an Outperform rating on Johnson & Johnson.

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$111.63

0.2 (0.18%)

21:03
08/22/19
08/22
21:03
08/22/19
21:03
Hot Stocks
Arbitration panel rules in favor of Eli Lilly in Adocia IP claim »

A Chicago-based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

FL

Foot Locker

$42.00

2.24 (5.63%)

, HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

20:25
08/22/19
08/22
20:25
08/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FL

Foot Locker

$42.00

2.24 (5.63%)

HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

RGR

Sturm, Ruger

$41.48

0.69 (1.69%)

, AOBC

American Outdoor Brands

$7.69

-0.01 (-0.13%)

19:40
08/22/19
08/22
19:40
08/22/19
19:40
Hot Stocks
Trump 'hopeful' to work with Congress on' legislation addressing mass shootings »

President Donald Trump…

RGR

Sturm, Ruger

$41.48

0.69 (1.69%)

AOBC

American Outdoor Brands

$7.69

-0.01 (-0.13%)

VSTO

Vista Outdoor

$5.33

0.26 (5.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 10

    Sep

  • 19

    Sep

TOT

Total

$48.98

-0.18 (-0.37%)

19:16
08/22/19
08/22
19:16
08/22/19
19:16
Downgrade
Total rating change at Citi »

Total downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPR

Kemper

$75.42

0.48 (0.64%)

19:14
08/22/19
08/22
19:14
08/22/19
19:14
Downgrade
Kemper rating change at William Blair »

Kemper downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 11

    Sep

CRM

Salesforce

$148.26

0.86 (0.58%)

, INTU

Intuit

$276.05

-0.29 (-0.10%)

18:52
08/22/19
08/22
18:52
08/22/19
18:52
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

CRM

Salesforce

$148.26

0.86 (0.58%)

INTU

Intuit

$276.05

-0.29 (-0.10%)

PVTL

Pivotal Software

$13.69

0.01 (0.07%)

CBLK

Carbon Black

$24.52

1.77 (7.78%)

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

RAVN

Raven

$31.36

-0.87 (-2.70%)

VMW

VMware

$148.15

0.11 (0.07%)

ROST

Ross Stores

$107.31

1.63 (1.54%)

GPS

Gap

$17.75

0.79 (4.66%)

HAS

Hasbro

$114.35

-1.06 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 04

    Sep

  • 10

    Sep

  • 25

    Sep

  • 10

    Oct

  • 27

    Oct

  • 12

    Dec

  • 16

    Dec

TLND

Talend

$39.24

0.12 (0.31%)

18:45
08/22/19
08/22
18:45
08/22/19
18:45
Hot Stocks
Talend CEO: We solve the first mile in the data journey »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.47

14.44 (4.25%)

18:40
08/22/19
08/22
18:40
08/22/19
18:40
Periodicals
FAA intends to test Boeing MAX software on newer pilots, Reuters says »

Next month, the FAA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

DB

Deutsche Bank

$7.17

0.155 (2.21%)

18:32
08/22/19
08/22
18:32
08/22/19
18:32
Periodicals
Deutsche Bank to pay $16M to settle corruption charges with SEC, Reuters says »

The SEC said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$292.36

-0.04 (-0.01%)

18:28
08/22/19
08/22
18:28
08/22/19
18:28
Periodicals
Kudlow says U.S., Chinese negotiators held productive trade talks, Reuters says »

White House economic…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$292.36

-0.04 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,188.53

-2.26 (-0.19%)

, GOOGL

Alphabet Class A

$1,190.41

0.15 (0.01%)

18:25
08/22/19
08/22
18:25
08/22/19
18:25
Hot Stocks
Google disabled 210 YouTube channels related to ongoing Hong Kong protests »

Google (GOOG) said in a…

GOOG

Alphabet

$1,188.53

-2.26 (-0.19%)

GOOGL

Alphabet Class A

$1,190.41

0.15 (0.01%)

FB

Facebook

$182.08

-1.48 (-0.81%)

TWTR

Twitter

$42.17

-0.63 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

NUAN

Nuance

$17.31

-0.14 (-0.80%)

18:24
08/22/19
08/22
18:24
08/22/19
18:24
Syndicate
Nuance files Form 10 registration statement for planned spin-off of Cerence »

Nuance Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$148.26

0.86 (0.58%)

18:23
08/22/19
08/22
18:23
08/22/19
18:23
Hot Stocks
Salesforce co-CEO: We had a very strong second quarter »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

RVLT

Revolution Lighting

$0.34

-0.0124 (-3.57%)

18:10
08/22/19
08/22
18:10
08/22/19
18:10
Hot Stocks
Revolution Lighting discloses additional delisting determination from Nasdaq »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$70.16

-0.38 (-0.54%)

18:05
08/22/19
08/22
18:05
08/22/19
18:05
Hot Stocks
Iberiabank CEO Daryl Byrd sells over $840K in company shares »

Iberiabank CEO Daryl Byrd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

RMNI

Rimini Street

$4.77

-0.11 (-2.25%)

, ORCL

Oracle

$53.18

-0.08 (-0.15%)

18:02
08/22/19
08/22
18:02
08/22/19
18:02
Hot Stocks
San Fang Chemical switches to Rimini Street support for Oracle EBS »

Rimini Street (RMNI)…

RMNI

Rimini Street

$4.77

-0.11 (-2.25%)

ORCL

Oracle

$53.18

-0.08 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$148.26

0.86 (0.58%)

18:01
08/22/19
08/22
18:01
08/22/19
18:01
Hot Stocks
Salesforce says Customer 360 will be huge growth driver over next decade »

Says: Momentum in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

AAC

AAC Holdings

$0.60

-0.0327 (-5.17%)

17:57
08/22/19
08/22
17:57
08/22/19
17:57
Hot Stocks
AAC Holdings discloses NYSE listing notice »

AAC Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

17:32
08/22/19
08/22
17:32
08/22/19
17:32
General news
Fed Balance Sheet Level data reported »

Week of 8/21 Fed Balance…

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

17:30
08/22/19
08/22
17:30
08/22/19
17:30
Hot Stocks
HP Inc. says notebooks accounted for 39% of revenue in Q3 »

Says supplies category…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

17:28
08/22/19
08/22
17:28
08/22/19
17:28
General news
Money Supply M2 Weekly Change data reported »

Week of 8/12 Money Supply…

TRPX

Therapix Biosciences

$2.35

(0.00%)

17:27
08/22/19
08/22
17:27
08/22/19
17:27
Syndicate
Breaking Syndicate news story on Therapix Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$141.38

-0.36 (-0.25%)

17:26
08/22/19
08/22
17:26
08/22/19
17:26
Hot Stocks
SPDR Gold Shares holdings rise to 854.84MT to 851.91MT »

This is the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$148.15

0.11 (0.07%)

17:19
08/22/19
08/22
17:19
08/22/19
17:19
Earnings
VMware sees Q3 adjusted EPS $1.42, consensus $1.57 »

Sees Q3 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Oct

CRWD

Crowdstrike

$93.04

-3.5 (-3.63%)

, CBLK

Carbon Black

$24.52

1.77 (7.78%)

17:14
08/22/19
08/22
17:14
08/22/19
17:14
Hot Stocks
Crowdstrike lower after Carbon Black acquisition »

Shares of cybersecurity…

CRWD

Crowdstrike

$93.04

-3.5 (-3.63%)

CBLK

Carbon Black

$24.52

1.77 (7.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.